Loading clinical trials...
Loading clinical trials...
Pomalidomide as an Immune-enhancing Agent for the Control of HIV (PEACH): An Investigator-initiated Phase I/IIb Clinical Trial in People Living With HIV on ART and During Analytical Treatment Interruption
Conditions
Interventions
Pomalidomide 2 mg
Placebo
+1 more
Locations
2
Australia
Royal Melbourne Hospital
Melbourne, Australia
Aarhus University Hospital
Aarhus, Denmark
Start Date
May 13, 2025
Primary Completion Date
March 31, 2026
Completion Date
March 31, 2026
Last Updated
June 27, 2025
NCT06602622
NCT06185452
NCT06902038
NCT04568603
NCT01511809
NCT03835546
Lead Sponsor
University of Aarhus
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions